BioXcel Therapeutics, Inc.
BTAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $15,159 | $85,931 | $601,762 | $536,163 |
| - Cash | $29,854 | $65,221 | $193,725 | $232,968 |
| + Debt | $102,947 | $101,384 | $94,156 | $1,398 |
| Enterprise Value | $88,252 | $122,094 | $502,193 | $304,593 |
| Revenue | $2,266 | $1,380 | $375 | $0 |
| % Growth | 64.2% | 268% | – | – |
| Gross Profit | $123 | $120 | $355 | -$297 |
| % Margin | 5.4% | 8.7% | 94.7% | – |
| EBITDA | -$44,161 | -$165,421 | -$157,217 | -$106,996 |
| % Margin | -1,948.9% | -11,987% | -41,924.5% | – |
| Net Income | -$59,599 | -$179,053 | -$165,757 | -$106,931 |
| % Margin | -2,630.1% | -12,974.9% | -44,201.9% | – |
| EPS Diluted | -23.51 | -98.35 | -94.67 | -64.87 |
| % Growth | 76.1% | -3.9% | -45.9% | – |
| Operating Cash Flow | -$72,027 | -$155,006 | -$135,341 | -$82,153 |
| Capital Expenditures | $0 | -$20 | -$139 | -$445 |
| Free Cash Flow | -$72,027 | -$155,026 | -$135,480 | -$82,598 |